[go: up one dir, main page]

WO2008061966A3 - Nouvelle utilisation de la flibansérine - Google Patents

Nouvelle utilisation de la flibansérine Download PDF

Info

Publication number
WO2008061966A3
WO2008061966A3 PCT/EP2007/062527 EP2007062527W WO2008061966A3 WO 2008061966 A3 WO2008061966 A3 WO 2008061966A3 EP 2007062527 W EP2007062527 W EP 2007062527W WO 2008061966 A3 WO2008061966 A3 WO 2008061966A3
Authority
WO
WIPO (PCT)
Prior art keywords
flibanserin
new use
ht2b
medicament
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/062527
Other languages
English (en)
Other versions
WO2008061966A2 (fr
WO2008061966A8 (fr
Inventor
Angelo Ceci
Marcus Schindler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim International GmbH
Publication of WO2008061966A2 publication Critical patent/WO2008061966A2/fr
Publication of WO2008061966A3 publication Critical patent/WO2008061966A3/fr
Publication of WO2008061966A8 publication Critical patent/WO2008061966A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne l'utilisation de la flibansérine dans la préparation d'un médicament pour traiter des maladies pour lesquelles l'utilisation de doses thérapeutiques efficaces de composés possédant une affinité avec le récepteur 5-HT2B présente un avantage thérapeutique.
PCT/EP2007/062527 2006-11-22 2007-11-20 Nouvelle utilisation de la flibansérine Ceased WO2008061966A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06124575.9 2006-11-22
EP06124575 2006-11-22

Publications (3)

Publication Number Publication Date
WO2008061966A2 WO2008061966A2 (fr) 2008-05-29
WO2008061966A3 true WO2008061966A3 (fr) 2008-07-10
WO2008061966A8 WO2008061966A8 (fr) 2008-09-04

Family

ID=39201544

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/062527 Ceased WO2008061966A2 (fr) 2006-11-22 2007-11-20 Nouvelle utilisation de la flibansérine

Country Status (1)

Country Link
WO (1) WO2008061966A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8324247B2 (en) 2008-10-22 2012-12-04 Ventrus Biosciences, Inc. Method for treating pulmonary arterial hypertension
CN103467596A (zh) * 2012-06-06 2013-12-25 北京大学 一个治疗肺动脉高压的新靶点

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1518858A1 (fr) * 2001-08-02 2005-03-30 BIDACHEM S.p.A. Polymorph stable de Fibanserin, procédé technique de préparation et utilisation pour la préparation de médicaments
US20050222176A1 (en) * 2003-03-31 2005-10-06 Dhanoa Dale S Piperidinylamino-thieno[2,3-D] pyrimidine compounds
US20060120972A1 (en) * 2004-11-09 2006-06-08 Peter Engels 9-(N-methyl-piperidyliden-4)-thioxanthene for treatment of pulmonary hypertension

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1518858A1 (fr) * 2001-08-02 2005-03-30 BIDACHEM S.p.A. Polymorph stable de Fibanserin, procédé technique de préparation et utilisation pour la préparation de médicaments
US20050222176A1 (en) * 2003-03-31 2005-10-06 Dhanoa Dale S Piperidinylamino-thieno[2,3-D] pyrimidine compounds
US20060120972A1 (en) * 2004-11-09 2006-06-08 Peter Engels 9-(N-methyl-piperidyliden-4)-thioxanthene for treatment of pulmonary hypertension

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BORSINI F ET AL: "BEHAVIORAL EFFECT OF FLIBANSERIN (BIMT 17)", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 64, no. 1, September 1999 (1999-09-01), pages 137 - 146, XP001055977, ISSN: 0014-2999 *
LONG LU ET AL: "Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice.", CIRCULATION RESEARCH 31 MAR 2006, vol. 98, no. 6, 31 March 2006 (2006-03-31), pages 818 - 827, XP002474423, ISSN: 1524-4571 *

Also Published As

Publication number Publication date
WO2008061966A2 (fr) 2008-05-29
WO2008061966A8 (fr) 2008-09-04

Similar Documents

Publication Publication Date Title
WO2007128802A3 (fr) Utilisation de flibansérine pour le traitement des troubles de la libido post-ménopausiques
EP2151435A4 (fr) Composition pharmaceutique pour le traitement de la maladie d'alzheimer
SI2044111T1 (sl) Ciljanje komplementa faktorja H za zdravljenje bolezni
WO2008076847A3 (fr) Délivrance régionale d'agents thérapeutiques pour le traitement de maladies vasculaires
IL213407A (en) Use of combinations of drug factors to prepare combination therapy drugs
IL210589A (en) C2386RV Protein Tuberculosis Kvfb Protein Use for the Treatment or Prevention of TB
IL216399A0 (en) Pharmaceutical composition for the treatment of heart diseases
HUE037974T2 (hu) Gyógyászati kompozíció Parkinson-kór kezelésére
IL207546A0 (en) Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
PL2056842T3 (pl) Modyfikowany galaktozyloceramid do leczenia chorób nowotworowych
WO2008076954A3 (fr) Composés hétérocycliques et procédés d'utilisation de ceux-ci
EP2094281A4 (fr) Utilisation de conjugués lipidiques dans le traitement de maladies ou de troubles oculaires
IL192415A0 (en) Pharmaceutical composition for the treatment of nail diseases
WO2010121164A3 (fr) Composés de 1,4-benzodiazépinone et leur utilisation dans le traitement du cancer
EP2306824A4 (fr) Administration par ionophorèse de curcumine et analogues de curcumine destinés au traitement de la maladie d'alzheimer
WO2006108582A3 (fr) Genes marqueurs humains et agents de diagnostic, de traitement et de prophylaxie des troubles cardio-vasculaires et de l'atherosclerose
WO2009099553A3 (fr) Utilisation d’inhibiteur de kinase pour le traitement de l’athérosclérose
TWI372056B (en) Novel medicament combinations for the treatment of respiratory diseases
EP2320939A4 (fr) Kallikréine tissulaire destinée au traitement de la maladie de parkinson
IL240394B (en) Use of alemtuzumab to prepare a drug for use as a secondary treatment in multiple sclerosis
WO2008031835A3 (fr) Méthode de traitement de maladies auto-immunes à l'aide d'inhibiteurs de la voie vegf
WO2011113000A8 (fr) Compositions inédites contenant des esters et méthodes associées
EP2026822A4 (fr) Traitement topique de maladies associées à la surface oculaire
PL1871399T3 (pl) Zastosowanie lecytyny jako leku w leczeniu łuszczycy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07847216

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07847216

Country of ref document: EP

Kind code of ref document: A2